Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

Single Cell Signaling Responses Stratify Immune and Leukemia Cell Populations in Acute Myeloid Leukemia

Kathryn I Sunthankar, MD, Benjamin J Reisman, BS, Candace H Cote, BS, Paul Brent Ferrell, Jr., MD

Blood (2019) 134 (Supplement_1): 2680.

https://doi.org/10.1182/blood-2019-129602

Published: 2019

Journal Articles

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Michael T Byrne, DO, Nathalie Danielson, MSN, Adrianne Rasche, MSN, Rachel Hammers, MSN, Kathryn A Culos, PharmD, Katie S Gatwood, PharmD, Houston Wyatt, PharmD, Kristin Fogo, BSN, Bhagirathbhai Dholaria, MBBS, Brian G Engelhardt, MD, Paul Brent Ferrell, Jr., MD, Madan Jagasia, MBBS, MS, MMHC, Adetola A. Kassim, MDMS, Sanjay R Mohan, MD MSCI, Bipin N. Savani, MD, Stephen A. Strickland, MD, Salyka M. Sengsayadeth, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2643.

https://doi.org/10.1182/blood-2019-129146

Published: 2019

Journal Articles

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Blood (2018) 132 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2018-99-114126

Published: 2018

Journal Articles

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Justin Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Shira Dinner, MD, Sangmin Lee, MD, Karen Seiter, MD, Thomas Prebet, MD PhD, Gary J. Schiller, MD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Hagop M. Kantarjian, MD, Patrick Kelly, MD, Ping Li, PhD, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2018-99-114263

Published: 2018

Journal Articles

IDH2 Mutations Induce Altered STAT Signaling and Cytokine Responses Which Are Restored By Enasidenib

Kathryn S Ivy, BA, Candace H Cote, BS, Paul Brent Ferrell, Jr., MD

Blood (2018) 132 (Supplement 1): 1468.

https://doi.org/10.1182/blood-2018-99-117783

Published: 2018

Journal Articles

Expression of S100A9 in Bone Marrow Cells Differentiates Refractory Cytopenia with Multilineage Dysplasia (RCMD) from Refractory Anemia with Excess Blasts (RAEB) and Acute Myeloid Leukemia (AML)

Paul Brent Ferrell, Jr., MD, Caroline R. Maier, BS, Mikael Roussel, MD PhD, Michael R. Savona, MD, Jonathan Michael Irish, PhD

Blood (2016) 128 (22): 4303.

https://doi.org/10.1182/blood.V128.22.4303.4303

Published: 2016

Journal Articles

Mutational Burden in Acute Myeloid Leukemia Is Largely Age Dependent

Aaron C. Shaver, MD PhD, Adam C. Seegmiller, MD PhD, Stephen A. Strickland, MD, Robert D. Daber, PhD, Sanjay R. Mohan, MD, Paul Brent Ferrell, Jr., MD, Cindy Vnencak-Jones, PhD, David R. Head, MD, Annette S. Kim, MD PhD, Mary M. Zutter, MD, Michael R. Savona, MD

Blood (2015) 126 (23): 2605.

https://doi.org/10.1182/blood.V126.23.2605.2605

Published: 2015

Journal Articles

Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Paul Brent Ferrell, Jr., MD, William Senapedis, PhD, Alexander Cook, Erkan Baloglu, PhD, Yosef Landesman, PhD, Jonathan Michael Irish, PhD, Michael R. Savona, MD

Blood (2015) 126 (23): 3686.

https://doi.org/10.1182/blood.V126.23.3686.3686

Published: 2015

NARROW

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Single Cell Signaling Responses Stratify Immune and Leukemia Cell Populations in Acute Myeloid Leukemia

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

IDH2 Mutations Induce Altered STAT Signaling and Cytokine Responses Which Are Restored By Enasidenib

Expression of S100A9 in Bone Marrow Cells Differentiates Refractory Cytopenia with Multilineage Dysplasia (RCMD) from Refractory Anemia with Excess Blasts (RAEB) and Acute Myeloid Leukemia (AML)

Mutational Burden in Acute Myeloid Leukemia Is Largely Age Dependent

Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only